The Committee for Medicinal Products for Human Use (CHMP) concluded that the INVANZ had shown its effectiveness, albeit with a limited number of severe cases treated during the trials, in the treatment of abdominal infections, community-acquired pneumonia, gynaecological infections, and diabetic foot infections.